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Abstract
Genetic variation within the major histocompatibility complex (MHC) contributes substantial risk for systemic lupus
erythematosus, but high gene density, extreme polymorphism and extensive linkage disequilibrium (LD) have made fine
mapping challenging. To address the problem, we compared two association techniques in two ancestrally diverse
populations, African Americans (AAs) and Europeans (EURs). We observed a greater number of Human Leucocyte Antigen
(HLA) alleles in AA consistent with the elevated level of recombination in this population. In EUR we observed 50 different
A—C—B—DRB1—DQA—DQB multilocus haplotype sequences per hundred individuals; in the AA sample, these multilocus
haplotypes were twice as common compared to Europeans. We also observed a strong narrow class II signal in AA as
opposed to the long-range LD observed in EUR that includes class I alleles. We performed a Bayesian model choice of the
classical HLA alleles and a frequentist analysis that combined both single nucleotide polymorphisms (SNPs) and classical
HLA alleles. Both analyses converged on a similar subset of risk HLA alleles: in EUR HLA– B∗08:01 + B∗18:01 + (DRB1∗15:01
frequentist only) + DQA∗01:02 + DQB∗02:01 + DRB3∗02 and in AA HLA–C∗17:01 + B∗08:01 + DRB1∗15:03 + (DQA∗01:02
frequentist only) + DQA∗02:01 + DQA∗05:01+ DQA∗05:05 + DQB∗03:19 + DQB∗02:02. We observed two additional independent
SNP associations in both populations: EUR rs146903072 and rs501480; AA rs389883 and rs114118665. The DR2 serotype was
best explained by DRB1∗15:03 + DQA∗01:02 in AA and by DRB1∗15:01 + DQA∗01:02 in EUR. The DR3 serotype was best
explained by DQA∗05:01 in AA and by DQB∗02:01 in EUR. Despite some differences in underlying HLA allele risk models in
EUR and AA, SNP signals across the extended MHC showed remarkable similarity and significant concordance in direction of
effect for risk-associated variants.
Introduction
Systemic lupus erythematosus (SLE) is a highly complex disease,
with occurrence heavily influenced by genetics (heritability =
44%; (1)). SLE incidence variesmarkedly across populations,with
Europeans (EURs) showing 3–4-fold lower prevalence compared
with individuals of African or Asian ancestry (2,3). Genome-
wide association studies (GWAS) indicate a strong genetic sig-
nal arising from the major histocompatibility complex (MHC)
in all populations studied (4–6). The association signals in the
MHC have been studied in EURs (7) and East Asians (8–10). In
EURs, the strength of the MHC signal seen in GWAS is driven
by multiple separate genetic factors. Unravelling these differ-
ent effects is hampered by extensive linkage disequilibrium
(LD). Two SLE-associated haplotypes that exhibit extended LD
have been described in EURs: the haplotypes include the HLA-
DRB1 alleles, HLA-DRB1∗03:01 and HLA-DRB1∗15:01. These two
haplotypes are also associated with other autoimmune dis-
eases (11,12) and are often referred to by their tagging HLA-
DRB1 alleles, with haplotypes containing DRB1∗03 alleles being
the ‘DR3’ serotype; haplotypes containing DRB1∗15 or DRB1∗16
alleles comprise the ‘DR2’ serotype. The actual causal alleles at
the MHC in EURs are unknown, a somewhat surprising situation
given the comparatively, in complex trait terms, large relative
risk of at least two conveyed by MHC alleles. The limitation has
principally been the extended LD at the MHC. In East Asian
SLE the MHC risk is also strong, but may be slightly simpler
than in EURs, the predominant risk arising from the extended
haplotypes including HLA-DRB1∗15:02 in LD with DQA1∗01 and
DQB1∗05 or ∗06 alleles (9,10). Investigation of the MHC associa-
tions in African Americans (AAs) has only previously been stud-
ied intensively in small cohorts and using limited genotyping
(13) or as part of a larger scan of immune-related loci using
the Immunochip (14) with limited information on HLA alle-
les. Small studies have implicated HLA-DRB1∗15:03-DQA1∗01:02-
DQB1∗06:0213 and a modest SNP-based study did suggest that
multiple MHC association signals were present (13). Population
admixture is a complicating factor in the genetic analysis in AAs.
The greater prevalence of SLE in non-EUR populations ratio-
nalizes a trans-ancestral approach to fine map genetic associ-
ation signals. We have previously employed this strategy at a
genome-wide level (15) and we have fine-mapped individual loci
identifying a single polymorphism, likely to be causal, close to
the transcription start of the SLE susceptibility gene, TNFSF4
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(16). In a small SNP-based study, we examined the pattern of
association with SLE at the MHC in northern and southern EUR
cohorts and in a Filipino population (10). Aligning the patterns of
association suggested some similarity but revealed differences
in LD around these association signals. These results suggest
that trans-ancestral fine mapping strategy at the MHC is of
value. A recent trans-ancestral study using the Immunochip (14)
did look at HLA and SNP associations in the MHC but was not
focused on the MHC and the analysis used a simple stepwise
approach with a generous level of statistical significance for
inclusion. The Immunochip study was also limited by a small
number of AA ancestry samples in the reference data used for
HLA imputation.
We have genotyped 1494 SLE cases and 5908 controls of AA
ancestry for genetic markers within the MHC, as part of a GWAS.
308 AA subjects were also genotyped for classical class II HLA
alleles and included in the reference data for HLA imputation.
These data were compared to an equivalent analysis of MHC
data from a recent GWAS in a EUR population (4). We performed
two parallel analyses to determine the model of association for
HLA alleles: 1) an analysis guided by the a priori view of causality
in the Class II region and 2) a fully Bayesian model choice. The
classical approach started from an assumption of association
at class II loci and was motivated by the observed association
signal in this area combined with the relatively short-range LD
in the AA population. The Bayesian approach used Reversible
Jump Markov Chain Monte Carlo (RJMCMC) simulation to search
over all possible HLA models of association, with defined priors
(see Materials and Methods) for genetic risk effects (odds ratios)
and model size (the number of causal variants). We found that
our two analyses strategies converged to very similar results for
association in the HLA region.
Results
We analysed genetic data across the MHC in AA and EUR for
association with SLE. The EUR data were taken from a previously
published GWAS (4) comprising 4036 cases and 6959 controls.
Post quality control (QC) (see Materials and Methods) there were
6079 SNPs in the MHC (Chr6, 26–34 Mb). 1494 cases and 5908 con-
trols of AA ancestry, genotyped as part of a GWAS (unpublished),
passed QC as did 4222 SNPs within the MHC.
We generated a new reference panel of HLA-typed individ-
uals in a subset of the AA data. A total of 308 subjects were
genotyped for classical class II HLA alleles (HLA∗DQA, HLA∗DQB
and HLA∗DRB1) by targeted sequencing of exons 2 and 3 (HLA-
DQA and HLA-DQB) and exon 2 (HLA-DRB1) (17). These were
added to the database of reference HLA genotypes for HLA
imputation with the software HLA∗IMPV2 (18). We imputed HLA
alleles in each populations’ data (see Materials and Methods)
using HLA∗IMPV2 and also imputed amino acid data (see Mate-
rials and Methods).
Overall patterns of MHC genetic association
We first investigated the single-marker association signals for
SNPs and HLA alleles across the MHC in both populations (AA
and EUR). EURs show extensive LD encompassing the entire
extendedMHC; in the AA data, the correlation is limited to a nar-
row peak in the HLA class II region (Fig. 1). The most significant
HLA signal in both EUR (HLA-DQB∗02:01, P-value = 4.3 × 10−95)
and AA (HLA-DRB1∗15:03, P-value = 7.0 × 10−25) is a class II
gene. Each of these HLA alleles tags well-known associated
haplotypes:HLA-DRB1∗03:01—HLA-DQA1∗05:01—HLA-DQB1∗02:01
(DR3) in EURs and HLA-DRB1∗15:03—HLA-DQA1∗01:02—HLA-
DQB1∗06:02 (DR2) in Africans. The most associated SNP in the
EUR data is tagging DR3 (R2 = 0.65 with HLA-DRB1∗0301 and
R2 = 0.74 with HLA-B∗0801) while the most associated AA SNP is
tagging DR2 (R2 with HLA-DRB1∗15:03 = 0.78 and R2 = 0.7 with
HLA-DQB1∗06:02). The two populations show a similar genetic
association signal overall as shown by the concordance in SNP
associations in Supplementary Material, Fig. S1.
Fine mapping the class II signal
We were interested to determine the most likely HLA alleles
that explained the class II signal in the AA and EUR data in
Figure 1. Therefore,we conducted a haplotype analyses followed
by a model selection analysis (see Materials and Methods and
Supplementary Material 1) in both populations. This approach
began with a focus on the two most associated class II DR-
DQ haplotypes in each population representing DR2 and DR3
(Fig. 2B-i).
In AA: DRB1∗15:03—DQA∗01:02—DQB∗06:02 (P-value =7.18 ×
10−22, OR = 1.74) and DRB1∗03:01—DQA∗05:01—DQB∗02:01
(P-value = 3.42 × 10−03, OR = 1.27).
In EUR: DRB1∗15:01—DQA∗01:02—DQB∗06:02 (P-value =8.23 ×
10−10, OR = 1.30) and DRB1∗03:01—DQA∗05:01—DQB∗02:01
(P-value = 2.58 × 10−95, OR = 2.32).
We found that DR2 was best explained by DRB1∗15:03 +
DQA∗01:02 in AA and by DRB1∗15:01 + DQA∗01:02 in EUR, while
DR3 was best explained by DQA∗05:01 in AA and by DQB∗02:01 in
EUR. These alleles are noted in Figure 2B-ii.
Stepwise regression on HLA alleles
Having determined the most likely explanation for the class
II association peak in each population, we then conditioned
on these models to find additional independently associated
HLA alleles. We ran a forward stepwise regression on all HLA
alleles starting from the class II HLA alleles just discussed
(see Supplementary Material 2). This biased approach to
stepwise regression, reassuringly, resulted (Fig. 2B-iii) in mainly
the same HLA alleles as a fully Bayesian agnostic analysis that
searched over all HLA alleles in classes I and II (seeMaterials and
Methods, Fig. 2B-i and Supplementary Material 3). The exception
being the models from this stepwise approach starting from
class II includes both the HLA-DQA∗01:02 and the HLA-DRB1∗15
alleles whereas the Bayesian model choice includes only HLA-
DQA∗01:02 in the EUR data and only HLA-DRB1∗15:03 in the AA
data (Table 1). The colour codes in Figure 2 highlight which HLA
alleles lay on the DR2 and DR3 risk haplotypes discussed above.
Other alleles, such as class I B∗18:01 in EUR and C∗17:01 in AA,
for example, are associated in addition to and independently of
the risk haplotypes.
Associations conditional on the HLA alleles
To search for SNP associations in addition to and independent
of HLA alleles, and to understand the independent regional
HLA associations, we ran stepwise regression conditional on
various sets of HLA alleles. Figure 3 displays association results
in a sequential fashion conditional on various sets of associ-
ated HLA alleles. Figure 3A and B show the results after condi-
tioning on the best model of association at class II; Figure 3C
and D are conditioning on the best model of association for
class II including the extended ancestral MHC DR3 haplotype
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Figure 1. Association signal across the extended MHC region in EUR and AA data. In each panel, the title contains the most significant genetic marker and its P-value.
A small black dot indicates the most significant marker. (A) LD with the most significant SNP in EUR. In EUR, a high level of LD exists across the entire extended MHC.
(B) LD with the most significant SNP in AA. In AA, LD with the most significant SNP is restricted to a single peak in class II. (C) Association signal in class I and class II
classical HLA alleles in EUR. The classical HLA alleles reflect the signal of the greyed-out SNPs from which they were imputed. (D) Association signal in classes I and II
classical HLA alleles in AA.
Table 1. AA association results for HLA alleles class II led stepwise regression
Conditional results (multiple regression) Single-marker results
ALLELE Odds Ratio 95% C.I. P Odds Ratio 95% C.I. P
HLA-C∗17:01 1.42 1.21–1.65 7.40E-06 1.25 1.08–1.42 2.64E-03
HLA-B∗08:01 1.75 1.41–2.17 1.01E-07 1.93 1.59–2.35 9.74E-12
HLA-DRB1∗15:03 2.03 1.73–2.37 1.47E-18 1.86 1.65–2.09 9.72E-26
HLA-DQA∗01:02 1.13 0.98–1.29 8.64E-02 1.23 1.11–1.36 5.22E-06
HLA-DQA∗02:01 0.31 0.19–0.49 1.14E-06 0.90 0.78–1.02 1.24E-01
HLA-DQA∗05:01 1.46 1.27–1.67 4.11E-09 1.38 1.22–1.54 9.52E-09
HLA-DQA∗05:05 0.17 0.07–0.35 4.74E-06 0.19 0.09–0.37 1.47E-06
HLA-DQB∗03:19 1.65 1.38–1.96 2.01E-09 1.62 1.38–1.89 9.85E-10
HLA-DQB∗02:02 6.23 3.53–11.0 1.50E-10 1.11 0.92–1.31 2.63E-01
Alleles in LD with HLA-DRB1∗03:01 (DR3) are coloured in red, and alleles in LD with HLA-DRB1∗15 (DR2) are coloured in purple. AIC = 7119, BIC = 7195.
(see Supplementary Material 4), which is effectively the class I
signal from HLA-B8. Figure 3E and F show residual association
after removing the signals from the best model of all HLA alleles.
After conditioning on the top HLA class II association signals
in each cohort, it is apparent that both cohorts show evidence
of additional association signals close to the junction of MHC
classes I and III regions. Class I HLA-B8 (or variants highly corre-
lated with it) makes a major contribution to both of these asso-
ciation signals, as the association spike is markedly diminished
when conditional onHLA-B∗08:01. Interestingly,when condition-
ing on the best overall model for HLA association there is limited
evidence for further signals in the EUR cohort; however, there
remains clear evidence for further association in the AA cohort
in the class III region (Fig. 3F).
The stepwise regression on SNPs only using each popula-
tion’s data and conditioning on the respective HLA alleles in
Figure 2iii returned two SNPs in the EUR data (rs146903072:
P-value = 3.93 × 10−06, OR = 1.82 95% CI 1.39–2.37, 31,847,180
bp, intergenic SLC44A4 – EHMT2; rs501480: P-value = 9.84 ×
10−06, OR = 1.15 95% CI 1.08–1.22, 33,563,946 bp,
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Table 2. EUR association results for HLA alleles in models of association from class II led stepwise regression
Conditional results (multiple regression) Single marker results
Stepwise regression
ALLELE OR 95% C.I. P OR 95% C.I. P
HLA-B∗08:01 1.63 1.45–1.83 1.13E-14 2.41 2.22–2.60 1.47E-93
HLA-B∗18:01 1.40 1.24–1.58 1.64E-07 1.28 1.14–1.44 3.03E-05
HLA-DRB1∗15:01 1.20 1.04–1.37 7.55E-03 1.32 1.22–1.43 4.53E-11
HLA-DQA∗01:02 1.27 1.13–1.42 6.74E-05 1.27 1.17–1.37 6.36E-11
HLA-DQB∗02:01 1.84 1.63–2.07 1.29E-24 2.32 2.14–2.50 4.34E-95
HLA-DRB3∗02 0.76 0.70–0.82 1.01E-10 0.70 0.65–0.76 5.46E-21
Alleles in LD with HLA-DRB1∗03:01 (DR3) are coloured in red, and alleles in LD with HLA-DRB1∗15 (DR2) are coloured in purple. AIC = 13319, BIC = 13392.
Figure 2. Models of association across HLA alleles. (A) Bayesian model choice fit using RJMCMC. (B-i) Most associated class II haplotypes, (B-ii) models with lowest AIC
and BIC comprising classes I and II alleles. (B-iii) Stepwise regression starting from the alleles in B-ii. Alleles in LD with HLA-DRB1∗03:01 (DR3) are coloured in red, and
alleles in LD with HLA-DRB1∗15 (DR2) are coloured in purple.
intergenic GGNBP1 – LINC00336) and two SNPs in the AA data
(rs389883:P-value = 4.37 × 10−08, OR = 1.76 95% CI 1.31–1.76,
31 947460 bp, intron STK19; rs114118665: P-value = 5.76 × 10−06,
OR = 2.37 95% CI 1.56–3.60, 31 342 005 bp, intergenic HLA-B –
MICA). The two associated SNPs in the AA data are not in LDwith
the two associated SNPs in the EUR data (R2 < 0.01 in all parings,
in both populations). We found no evidence of association for
the AA SNPs in the EUR data (as single markers of conditional
on the HLA) and vice versa.
The HLA-DQ heterodimer risk profile
As the cell surface HLA-DQ molecule is a heterodimer with
variation in both its alpha (coded DQA) and beta (coded DQB)
chains, we explored the hypothesis that a combination of DQA
and DQB alleles would be a better model fit than including
the alleles as independently associated. We found no evidence
(see Materials and Methods) in favour of an interaction model
between any pair ofDQA andDQB alleles. Furthermore,we found
no specific combination of DQA and DQB alleles that fit the
data better than simple additive models. This suggests that the
effects of DQA and DQB alleles are independent.
Two-digit DRB1∗15 association and amino acid data
We looked closely at the association signals for HLA alleles
nested within the two-digit HLA-DRB1∗15 group, as these alleles
are consistently associated with SLE across major populations
yet differ in frequency and in the most associated allele. The
DRB1∗15:03 allele is the most associated DRB1∗15 allele in the
AA cohort (P-value = 1 × 10−25, OR = 1.86 95% C.I. =1.66–
2.09); however we did observe DRB1∗15:01 (frequency = 3.3%)
and DRB1∗15:02 (0.3%) alleles with association P-values of
0.03 and 0.46, respectively, and effect size estimates of 1.32
(95% C.I. 1.03–1.69) and 1.50 (95% C.I. 0.50–4.46). In the EUR
data where DRB1∗15:01 is the most associated DRB1∗15 allele
(P-value = 4.53 × 10−11, OR = 1.32 95% C.I. =1.22–1.43), we also
observe DRB1∗15:02 (frequency = 0.8%) but with no evidence
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Figure 3. Class II informed conditional analyses. EUR (A) and AA (B) SNP and classical HLA allele association signals after conditioning on the best class II model
(EUR: HLA-DRB1∗15:01 + HLA-DQA∗01:02 + HLA-DQB∗02:01; AA: HLA-DRB1∗15:03 + HLA-DQA∗01:02 + HLA-DQA∗05:01). EUR (C) and AA (D) SNP and classical HLA allele
association signals after conditioning on the best class II + I model (EUR:HLA-DRB1∗15:01 + HLA-DQA∗01:02 + HLA-DQB∗02:01 + HLA-B∗08:01; AA:HLA-DRB1∗15:03 + HLA-
DQA∗01:02 + HLA-DQA∗05:01 + HLA-B∗08:01). EUR (E) and AA (F) SNP and classical HLA allele association signals after conditioning on the best overall HLA model (EUR:
HLA-DRB1∗15:01 + HLA-DQA∗01:02 + HLA-DQB∗02:01 + HLA-DR3∗02:01 + HLA-B∗08:01 + HLA-B∗18:01; AA: HLA-DRB1∗15:03 + HLA-DQA∗01:02 + HLA-DQA∗02:01 + HLA-
DQA∗05:01 HLA-DQA∗05:05 + HLA-DQB∗03:19 + HLA-DQB∗02:02 + HLA-B∗08:01 + HLA-C∗07:01).
(P-value = 1.86 × 10−01, OR = 0.81 95% C.I. =0.59–1.12) for
association. DRB1∗15:02 has been found to be associated in East
Asians (9), DRB1∗15:01 has also been found to be associated in
this population (19).
We tested a one-parameter two-digit DRB1∗15 allele model
against a three-parameter (a separate odds ratio for each allele:
DRB1∗15:01 + DRB1∗15:02 + DRB1∗15:03) model in the AA data.
We did find weak evidence (P-value = 0.02) to reject the two-
digit model using a likelihood ratio test; however the Bayesian
Information Criterion (BIC) favoured the two-digit model (differ-
ence in BIC = 10.37). This has some biological significance as the
three HLA alleles share the same amino acid residue at position
71 (A) and no other HLA-DRB1 allele amongst those imputed in
the AA dataset codes for this residue at this position. The two-
digit model of association is therefore equivalent to an amino
acid residue association.
Comparison of HLA, amino acid and SNP models of
association
An important question is whether the association signal across
the MHC can be best explained by SNPs, HLA alleles or amino
acid residues. To explore this we compared our results for HLA
association to those obtained by stepwise regression analyses on
amino acid and SNP data (Table 3). In both populations’ analyses
we found that the amino acid models were a poorer fit than
HLA alleles, as judged by the Akaike Information Criterion (AIC)
or BIC. In the AA data, the HLA model was the best overall
fit. In the EUR data, the SNP model was the best fit. The SNP
model in the AA data is likely not tagging all the SLE-associated
variation, in support of this interpretation we did find two fur-
ther independent HLA associations, namely HLA∗DQA∗05:05 and
HLA∗DRB1∗13:04, conditional on the four SNPs noted in Table 4.
The HLA alleles tagged by the SNP models can be seen in Sup-
plementary Material, Fig. S3, and for reference the full set of
HLA frequencies and associations can be seen in Supplementary
Material, Fig. S4.
Autoantibody sub-phenotypes
We had data available on autoantibody levels in both pop-
ulations, so we exploited this and present here novel cross-
population genetic association analyses of these phenotypes.
In EUR the anti-Ro autoantibody was present in 851 of 2492
cases (34%). We found two independent significant associations
with both anti-Ro and anti-La in case-only analyses. The most
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Table 3. Association results for amino acid data from stepwise regression in the AA data
Conditional results (multiple regression) Single-marker results HLA alleles specific to amino acida
ALLELE OR 95% C.I. P OR 95% C.I. P
DRB1 71A 2.22 1.97–2.49 2.82E-40 1.72 1.55–1.91 1.07E-24 DRB1∗15:01, :02, :03
DQB -18A 1.63 1.48–1.80 1.19E-22 1.20 1.10–1.30 3.34E-05 DQB∗02:01, :02, :03, 03:01, :04, :09, ∗03:19, ∗06:01
B 156D 1.57 1.40–1.76 2.20E-15 1.42 1.28–1.58 1.80E-10 B∗08:01, ∗37:01, :41, :42, :45, :82
DQA -13 T 0.11 0.05–0.22 2.26E-09 0.19 0.09–0.37 1.47E-06 DQA∗05:05
aThese are the HLA alleles that are specific to the amino acid, for example, the only HLA alleles observed in our data that code for DRB-71-A are DRB1∗15:01,
DRB1∗15:02 and DRB1∗15:03. See Supplementary Material, Fig. S4 for HLA alleles’ frequencies in our data. AIC = 7163, BIC = 7211.
Table 4. Association results for SNPs from stepwise regression in the AA data. AIC = 7176, BIC = 7224
Conditional results (multiple regression) Single-marker results
SNP Effect (Other) Allele OR 95% C.I. P OR 95% C.I. P
RS9271413 G (A) 2.07 1.84–2.33 4.69E-34 1.72 1.56–1.91 8.30E-26
RS9273481 C (G) 1.45 1.32–1.60 3.80E-14 1.19 1.09–1.29 6.56E-05
6:31323500:D D (I) 1.48 1.31–1.68 7.79E-10 1.47 1.30–1.65 2.28E-10
RS115549526 T (C) 1.60 1.36–1.18 1.33E-08 2.13 1.83–2.49 6.12E-22
Table 5. Association results for amino acid data from stepwise regression in the EUR data
Conditional results (multiple regression) Single-marker results HLA alleles specific to amino acida
ALLELE OR 95% C.I. P OR 95% C.I. P
DRB1 77 N 2.02 1.78–2.30 2.86E-27 2.30 2.13–2.49 1.24E-93 DRB1∗03:01, :02
DQA 207 M 1.50 1.39–1.62 9.40E-25 1.27 1.18–1.36 6.36E-11 DQA∗01:02
B 9D 1.66 1.47–1.87 1.90E-16 2.42 2.22–2.63 1.47E-93 B∗08:01, ∗39:12
DRB1 233 T 1.24 1.16–1.33 3.25E-09 0.85 0.81–0.90 7.06E-08
DRB1∗15:01, :02, ∗01:01, :02, :03, ∗04:01,
:02, :03, :04, :05, :07, :08, :10, ∗07:01,
∗08:01, :03, :04, :10, 09:01, ∗10:01, ∗16:01
B 30G 1.34 1.18–1.52 4.39E-06 1.28 1.14–1.44 3.45E-05 B∗18:01, :03
aThese are the HLA alleles that are specific to the amino acid. See Supplementary Material, Fig. S4 for HLA alleles’ frequencies in our data. AIC = 13335, BIC = 13409.
Table 6. Association results for SNPs from stepwise regression in the EUR data. AIC = 13241, BIC = 1333
Conditional results (multiple regression) Single-marker results
SNP Effect (Other) Allele OR 95% C.I. P OR 95% C.I. P
RS141910407 T (C) 1.52 1.29–1.81 1.18E-06 2.71 2.47–2.97 3.93E-99
RS9260 A (G) 1.51 1.40–1.63 6.41E-27 1.33 1.24–1.43 2.17E-15
RS9273336 T (C) 1.84 1.62–2.08 1.43E-21 2.18 2.01–2.35 1.24E-85
X6:31428746:I I (D) 1.35 1.21–1.51 1.29E-07 2.12 1.97–2.28 6.59E-87
RS9270807 G (A) 1.25 1.17–1.34 6.00E-10 0.87 0.82–0.92 1.71E-06
RS2293861 C (T) 1.27 1.16–1.38 1.03E-07 1.48 1.36–1.61 5.78E-20
RS142903940 G (A) 1.19 1.11–1.29 3.79E-06 1.03 0.96–1.11 3.56E-01
RS501480 C (T) 1.15 1.08–1.22 7.83E-06 1.22 1.15–1.29 2.26E-11
significant anti-Ro association was a class I SNP rs115924783
(31 316 080 bp; OR = 2.05 95% CI 1.76–2.39; P-value = 3.12 × 10−20)
in tight LD with the classical class I allele B∗08:01 (r2 = 0.97,
EUR data). The most significant anti-La association rs114469371
(32 189921 bp; OR = 2.04 95% CI 1.70–2.45; P-value = 3.45 × 10−14)
was less correlated with B∗08:01 (r2 = 0.60, EUR data). The
secondary independent associations were rs9272780 (anti-Ro;
OR = 0.62 95% CI 0.53–0.71; P-value = 2.26 × 10−11) and rs3763355
(anti-La; OR = 0.38 95% CI 0.24–0.62; P-value = 8.53 × 10−06).
We also found significant SNP associations with anti-RNP
(rs147810605; 32,490,331 bp; P-value = 5.36 × 10−09) and anti-
dsDNA (rs116794933; 31,113,275 bp; P-value = 9.75 × 10−06).
Apart from rs115924783 and rs114469371 (correlated with
HLA-B8) none of the other SNP associations had high (r2 > 0.6,
EUR data) with any HLA alleles.
In AA, the anti-Ro autoantibody was present in 392 of
1200 AA cases (33%). We found some evidence of association
between anti-Ro and B∗08:01 (OR = 1.67; 95% CI = 1.16–2.42;
P-value = 6 × 10−03); however B∗08:01 has a lower frequency in
AA (7.2%) compared with EUR (20.4%) controls. The only sta-
tistically significant association with anti-Ro was a ‘protective’
one and that was with DRB1∗15:03 (OR = 0.48, 95% CI = 0.36–0.61,
P-value = 2.13 × 10−08).DRB1∗15:01was not associated with anti-
Ro in EUR (OR = 1.14, 95% CI = 0.96–1.34, P-value = 1.39 × 10−01).
We did not find significant evidence of association between
DRB1∗15:03 and anti-RNP (461 cases positive) or anti-Sm
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(420 cases positive) (P-value = 1.11 × 10−03 and P-value = 1.11 ×
10−02, respectively), although there was a trend for a risk effect
(OR = 1.45; 95% C.I. = 1.67–1.79 and OR = 1.34; 95% CI = 1.06–
1.69, respectively). We found no significant associations
(all P-value > 0.01) between DQA or DQB alleles and anti-RNP
or anti-Sm in the AA data.
Discussion
Our analyses of SNP, HLA and amino acid data in the MHC in an
AA and EUR population have identified the key HLA alleles that
are associated with SLE together with two SNPs independently
associated in both populations. We found models using HLA
alleles were a better fit to the data than amino acids’ models
in both the AA and EUR data. There is a similar landscape of
association with two independent class II associations in both
populations.
Our results for HLA associations are not the result of a single
analyses using stepwise regression, as is common in analysis
of a single region such as the MHC. We used two approaches:
a frequentists approach to decomposing class II-associated hap-
lotypes followed by conditional analyses and a Bayesian model
choice that searches over the full model space of HLA alleles.
The two approaches resulted in largely the same set of HLA
alleles, while the Bayesian approach was more parsimonious
by only including DQA∗01:02 as associated in the EUR data,
rather than both DRB1∗15:01 and DQA∗01:02. In addition, the
Bayesian approach included only DRB1∗15:03 as associated in
the AA data, rather than both DRB1∗15:03 and DQA∗01:02. In
both cases the pair of alleles is in LD (r2 = 0.61 and r2 = 0.37
in each population, respectively) and this discrepancy between
the approaches demonstrates some uncertainty remains on this
particular haplotype. There is some suggestion that the DRB1∗15
two-digit allele could be the best explanation in both popula-
tions for one of the main class II haplotypes associated, and this
could be further explained by a specific amino acid coding at
position 71 (A) for DRB1∗1501, DRB1∗1502 and DRB1∗1503.
The class II DR3 haplotype harbouring the commonly
observed SLE-associated DRB1∗03:01 allele was best explained
by DQB∗02:01 in the EUR data and DQA∗05:01 in the AA data.
The LD between these two alleles is much lower in the AA than
EUR data (r2 = 0.33 versus r2 = 0.92); thus there is more power to
resolve the DR3 class II associations in AAs. Our results suggest
that DQA∗05:01 is the most likely causal HLA class II allele on
this haplotype. This and the lack of extended LD, as illustrated in
Figure 1, suggest that the AA data have been very useful here in
finemapping both the HLA alleles and independently associated
SNPs. Both populations have evidence of additional independent
associations in class I with B∗08:01 being a consistent associated
allele in the two populations.
Our findings of SNP associations independent of HLA alleles
do show some consistency in the identification of two class
II/III SNPs independently associated in both populations, but
they also highlight some uncertainty and hence the need for
more extensive sequencing at the MHC including accurate HLA
typing.
WefindnovelHLA-DQ associations in theAAdata (DQA∗02:01,
DQA∗05:05 and DQB∗02:02). There is no difference in the peptide-
binding groove when replacing DQA∗05:05 with DQA∗05:01,
which captures the DR3 signal in the AA represented by
DQB∗02:01 in the EURs. The only difference between the two
products is in the 11th codon in the leader sequence [position
−13; DQA∗05:01 has GCC (alanine, non-polar and hydrophobic);
DQA∗05:05 has ACC (threonine, polar and hydrophilic). There-
fore, the primary amino acid sequences of the two mature
proteins are identical and should exhibit identical disease
susceptibility. However, we did not sequence exon-1 of DQA;
hence the genotyping is dependent on imputation and this,
together with DQA∗05:05 being rare in AA, leads to some
uncertainty in this allele’s association.
The DQA∗02:01 and DQB∗02:02 alleles’ associations seem
complex as these two HLA alleles are in LD with one another
(R2 = 0.87 in the AA data); they show conditional association
with a likely dominant effect for DQA∗02:01 (OR = 0.67; 95% C.I.
= 0.60–0.76; P-value = 1.31 × 10−11). It seems that DQB∗02:02 only
has a significant risk effect when conditioned on the protective
(possible dominant) effect of DQA∗02:01. We find no evidence
of interaction between HLA-DQA∗02:01 and HLA-DQB∗02:02. Due
to the two alleles being in strong LD this result could be due to
omitted variable bias, which would result in each of the allele’s
effect being shrunk to zero when not including both correlated
variables in a model of association.
We found a significant association between B∗08:01 and
anti-Ro antibodies in a case-only analysis of the EUR data
(OR = 2.03 95% CI 1.74–2.36; P-value = 4.02 × 10−19). While a
class I SNP was more associated than the HLA allele, due to
imputation uncertainly we cannot rule out this HLA allele as
more likely causal, which would be an interesting finding in
the light of the suspected role of Epstein Barr Virus (EBV) in
SLE pathogenesis. B8 binds an immune-dominant peptide from
EBV EBNA antigen (20,21). This association was also seen in the
AA data, but it was less significant (OR = 1.67 95% CI 1.16–2.41;
P-value = 6.13 × 10−03).
In summary this study substantially extends our understand-
ing of MHC association in SLE with the inclusion of a large-scale
study of AA samples and combining with a new analysis of a
large EUR dataset.Wehave novel HLA typing included in a subset
of the AA dataset, which greatly improves imputation. We find
similarity between the AA and EURs in their pattern of associ-
ation across the MHC using novel and coherent fully Bayesian
analyses to determine the best model of association with HLA.
The AA data highlight strong evidence for association at class II
independent of other loci. This has shown that comparing the
results of the MHC associations in EURs and AAs assists in fine
mapping these signals.
Materials and Methods
Samples and genotyping
EURs: The EUR data were taken from a previously published
GWAS (4) comprising 4036 cases and 6959 controls. Post
QC (which included MAF > 0.01, differential missingness
P-value < 5 × 10−07 and SNP missingness <0.05) there were
6079 SNPs in the MHC.
AAs: 1494 cases and 5908 controls of AA ancestry, genotyped
as part of a GWAS (unpublished), passed QC. These were geno-
typed on the following chips: OMNI2.5 (1509 controls), Omni 1
(1494 cases and 1099 controls) and Omni Express (3300 controls).
Post QC there were 4222 SNPs within the MHC. SNPs were
removed if they had greater than 2% missing data across all
samples, a P-value <0.05 for a test of differential missing data
between cases and controls, a Hardy Weinberg Equilibrium test
in cases with P-value <10−04 or a Hardy Weinberg Equilibrium
test in controls with P-value <10−02.
Samples were removed if their call rates <90% across good
quality SNPs, had excess autosomal heterozygosity or if their
genetically determined sex differed from their reported sex.
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Additionally, duplicate samples and first-degree relatives were
removed.
A total of 308 subjects were also genotyped for classical class
II HLA alleles (HLA∗DQA, HLA∗DQB and HLA∗DRB1) by targeted
sequencing of exons 2 and 3 (HLA-DQA and HLA-DQB) and exon
2 (HLA-DRB1) (17). This set included the ‘HLA reference set’
used for HLA imputation into the rest of the AA study. These
were added to the database of reference HLA genotypes for HLA
imputation with the software HLA∗IMPV218.
SNP imputation
All AA and EUR subjects were imputed up to the 1000 Genomes
(Phase I integrated set V3 March 2012) density using post-QC
typed SNPs using IMPUTE (22). All populations’ reference data
were used for imputation in the AA and EUR data as advised
by the authors of IMPUTE. We set a quality threshold of 0.7 for
IMPUTE INFO score and only analysed SNPs with scores above
this level.
HLA allele imputation
HLA genotypes for HLA-A, HLA-B, HLA-C, HLA-DQA, HLA-DQB
and HLA-DRB1 were imputed into the AA data using HLA∗IMP-
V2 (18). The same procedure was used to impute HLA alleles in
the EUR data for the classical HLA genes: HLA-A, HLA-B, HLA-C,
HLA-DQA, HLA-DQB, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5
and HLA-DPB1. While the same reference data was used to
impute both the AA and EUR data, the additional HLA alleles
imputed in the EUR data were not supported for multi-ethic
samples in the HLA∗IMP algorithm and so were not imputed in
theAAdata.HLA-IMP-V2 usesmulti-ethnic samples as reference
data including data from the 1958 British Birth Cohort, 1000
genomes subjects and additional, mainly EUR, data provided by
GlaxoSmithKline. Full details of these samples can be seen in
the publication paired with this software (18). Our contributed
AA samples to the reference data increased the size of the
AA/African background set, which was 28, 34 and 28 for HLA-
DQA1, HLA-DQB1 and HLA-DRB1, respectively, by over 10-fold.
For regression analyses we took the probabilistic genotypes
(rather than best guess) output and converted to dosage
(expected allele counts). For phasing and haplotype analyses
we took the best guess genotypes.
HLA imputation assessment
HLA∗IMP-V2 (18) performs cross validation on all reference sam-
ples (two-thirds are used for reference and one-third, for valida-
tion) as an indicative evaluation of imputation performance. The
results of this can be seen in Supplementary Material, Table S1
for the AA data on subjects in the ‘African’ HLA-IMP-V2 reference
data combined with our contributed AA samples. This table also
contains HLA-A, HLA-B and HLA-C; however these analyses were
performed on reference samples outside of our study.
We also performed our own imputation accuracy assessment
on the 308 HLA-typed subjects that were also included in our
association study. These results can be seen in Supplemen-
tary Material, Table S2–Supplementary Material, Table S4. This
assessment is biased upwards for accuracy estimation, as the
samples tested were also in the reference panel. However. the
results are comparablewith that returned byHLA∗IMP-V2,which
performed leave one-third out cross-validation on data that
included our samples, with HLA-DRB1 performing slightly worse
than HLA-DQA and HLA-DQB.
Amino acid translation
Amino acid sequences for each HLA allele were extracted
from the European Bioinformatics Institute HLA database
(http://www.ebi.ac.uk/ipd/imgt/hla/). HLA allele dosages were
converted to amino acid dosages at each position; the dosage
for a particular amino acid ‘A’ at position ‘p’ would be the sum
of HLA alleles’ dosage that coded for amino acid ‘A’ at position
‘p’. The total dosage for each position is therefore equal to 2 and
this total is split between each possible amino acid possible at
the position.
Phasing
The HLA data were phased together with the SNP data using
BEAGLE (23) to aid the classical statistical analysis of the SLE HLA
risk haplotypes.
AA admixture analysis
The AA data were subject to an analysis for admixture using
ADMIXTURE (24) on an LD-pruned dataset containing the AA
samples as well as Hapmap3 (CEU, CHB and YRI) samples as
anchoring populations. The resulting admixture estimates were
used to remove genetic outliers. We also used this analysis
to infer a set of subjects with a lower content of non-African
derived haplotypes. This analysis was performed on genome-
wide SNP data and onMHC-wide SNP data; results can be seen in
SupplementaryMaterial, Figure S4.The set of subjects chosen for
HLA typing was all within the African cluster in the MHC-wide
admixture analysis.We created a ‘more African’ subset of the AA
data by removingAA subjects thatwere in the top 25th percentile
of the non-African derived haplotypes estimate, which would
have retained all Africans in theHapMapdata; the data consisted
of 1375 cases and 5414 controls. We refer to these data as AAsub.
Statistical analysis
Study design. We began with parallel frequentist and Bayesian
association tests to determine the best underlying HLA risk
model for SLE. After determining the best model of association
at the HLA, we conditioned on this model, using classical step-
wise regression, and tested for further association with SNPs. A
workflow can be seen in Figure 4; we expand on each step in the
description below. We also tested for association with SLE sub-
phenotypes using classical stepwise regression.
Association analysis. Association analyses were performed in R
(25) using logistic regression. SLE status was coded as 0 (Healthy
controls) and 1 (cases). The SNP and HLA data were coded as
minor allele counts (0 < g < 2) with imputed SNPs and HLA
alleles coded as expected allele counts where the expectation
was taken from the imputation probabilities: Expectation = 0
X P(G = 0) + 1 X P(G = 1) + 2 X P(G = 2), where P(G = j), for
j = 0,1,2, is the probability of 0, 1 or 2 copies of the HLA or SNP
reference allele. These probabilities were taken from the output
of HLA∗IMP V2. Covariates derived from an admixture analysis
using ADMIXTURE (24) were used to account for population
structure in the AA data. Our AA data were combined with
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Figure 4. Work flow chart for analyses strategy. To determine the best model of association over HLA alleles, a Bayesian approach to model selection (left) was taken
in parallel to a classical model choice (right). Following this a classical stepwise regression on SNPs was performed conditional on HLA alleles returned by the model
choice.
HapMap European (CEU), African (YRI) and Asian (CHB + JPT)
populations and we used the admixture proportions of CEU and
YRI as covariates (the third proportion, assumed to be of Asian
ancestry, being redundant as all sum to 1).
Analysis of extended MHC haplotypes. We used likelihood ratio
testing between nested models of association with each of the
SLE-associated class II haplotypes to find the best set of alle-
les that explained the association. This was complimented by
checking the AIC and BIC for each model.
For example, in Supplementary Material, Table S6 where we
look at the DRB∗15:03—DQA∗01:02—DQB∗06:02 haplotype in the
full AA data, we see that a simple model with a DQA∗01:02—
DQB∗06:02 haplotype is rejected in favour of a model with
the addition of DRB∗15:03 as an extra explanatory variable
(P-value = 5.92 × 10−10), likewise a simple model with a
DRB∗15:03—DQB∗06:02 haplotype is rejected in favour of a
model with the addition of DQA∗01:02 as an extra explanatory
variable (P-value = 2.04 × 10−02). So in both cases the addition of
DRB∗15:03 or DQA∗01:02 is favoured. In the first case the addition
of DRB∗15:03 results in a lower AIC and BIC, while in the second
case the addition of DQA∗01:02 results in a lower AIC but not a
lower BIC. However, at this four-digit resolution the best model
as judged by the AIC is the model with DRB∗15:03 + DQA∗01:02
as separate additive explanatory variables, while the BIC is the
lowest for inclusion of only DRB∗15:03. At two-digit resolution
for DRB∗15; however the model with DRB∗15: + DQA∗01:02 as
separate additive explanatory variables is best as judged by the
BIC and AIC.
Bayesian association analysis. A Bayesian model selection was
performed on the HLA data using the association studies toolkit
for WinBUGS, employing a reverse jump algorithm on the model
space, in the Markov Chain Monte Carlo (MCMC) framework (28).
This approach used a probit link (rather than a logit link com-
monly used for case control association studies). The advantage
is that the MCMC algorithm samples from an underlying nor-
mally distributed variable (zi) where the probability of disease for
subject i is defined as p(zi > 0 | Mi) where themean parameter Mi
depends on a regression on the genotype values: Mi = beta ∗ Gi,
with Gi the genotype (the number of minor alleles for indi-
vidual i) and beta is the regression parameter. We made simple
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prior assumptions: first that the magnitude of genetic effect
(Odds ratio) could with non-negligible probability be in the range
0.25–4, and second that the genetic model would be most likely
to have 3–5 genetic effects but much less likely to have more
than 10 effects. We therefore used a Poisson distribution with
mean parameter equal to 4; however we tested the robustness
of our approach by re-running the analyses with Poisson (3) and
Poisson (5). For the prior on the effect sizes we used a normal
distribution with mean = 0 and variance = 0.25. This reflects the
belief that the beta parameter is relatively unlikely to be larger
than 1 (two standard deviations in our prior). A value of 1 on
the probit scale, with samples sizes similar to the ones in our
study, transfers to a relative risk of ∼1.7 and so most of our prior
belief in the relative risk is between 0.5–2, while values below 0.5
and above 2 are allowed but with less belief. It is important to
have informative priors in Bayesianmodel choice as vague priors
can overly favour the null model (zero effect size or equivalently
no explanatory variables in the chosen model). Our priors are
informative but not overly so, reflecting the commonly observed
risk effects in GWAS.
The MCMC model fitting in WinBUGS is a computationally
expensive exercise; however it was feasible within a period of
2 days to get results. The MCMC framework is a sampling-
based technique that requires convergence. With the current
AA and EUR data we found that running six chains in parallel
each of 80 000 samples with a burn-in period (where samples
are discarded) of 20 000 was sufficient. This required a 12-core
desktop PC with two 2.4 GHz Xeon processors and utilized 10GB
of RAM.
The HLA-DQ heterodimer risk profile. We tested for interaction
between all DQA-DQB pairs noted in Figure 2. For example, in the
case of EUR we tested for interaction between DQA∗01:02 and
DQB∗02:01.
We also created a variable from the product of the two
DQA and DQB pairs and tested this as a sole variable in the
regression; we then compared the AIC and BIC for this single-
variablemodel to the two-parametermodels (independent addi-
tive effect for the DQA and DQB alleles). This single-parameter
model captures risk attributable to the specific DQ molecules
created by the pairing, for example, the variable created from the
product of DQA∗01:02 × DQB∗02:01 gives the expected number
of DQA∗01:02/DQB∗02:01 molecules that could be expressed by
an individual: an individual with one copy of DQA∗01:02 and
two copies of DQB∗02:01 can make two molecules consisting of
DQA∗01:02/DQB∗02:01, while an individual with two copies of
DQA∗01:02 and two copies ofDQB∗02:01 canmake fourmolecules
consisting of DQA∗01:02/DQB∗02:01.
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